Predictive Model for Hypoglycaemia Risk in Type 2 Diabetes Mellitus Patients During the Peri-Colonoscopy Period: A Retrospective Cohort Study.
Haiyan Yang, Linlin Zhang, Huiling Liu and 5 others
PMID 39957511WHAT IT FOUND
A risk model for adults with type 2 diabetes undergoing colonoscopy flagged insulin use, fasting after the procedure, low C-peptide and reduced kidney function as risk factors, while SGLT2 inhibitor use was associated with lower risk.
Key findings
01Hypoglycaemia occurred in 112 of 598 patients (18.7%), with 43 before colonoscopy, 61 after and 8 both before and after.
02The final predictive model included insulin, SGLT2 inhibitors, fasting after colonoscopy, fasting C-peptide and eGFR.
03The model's ability to separate patients with and without hypoglycaemia was 0.78 in the development cohort and 0.82 in the validation cohort.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study is retrospective, so it shows associations, not that any factor caused hypoglycaemia. It came from one hospital, and patients were usually admitted for colonoscopy, so it may not apply to outpatient settings in other regions. Hypoglycaemia and predictors were taken from electronic records, so missed or poorly documented events and variables could bias the model. The model was internally validated only; external validation in other populations and settings is still needed. Different bowel preparation protocols and timing were not analysed.
Declared interests
The authors declared no conflicts of interest. The work was funded by the Sanming Project of Medicine in Shenzhen.
The easy way to misread this
Do not read the model as a tested intervention or as proof that changing these factors prevents hypoglycaemia. It is a retrospective single-centre prediction model that has not been externally validated or shown to improve patient outcomes.